Geriatric cachexia is associated with anorexia, involuntary weight loss, infections, decubitus ulcers, malnutrition, cognitive and psychiatric disorders, and even death (1). Yeh and Schuster stated that, of these conditions, only malnutrition is amenable to medical intervention. I propose that magnesium replacement therapy be considered as a therapy in geriatric cachectic patients found to be magnesium deficient.
Magnesium is the fourth most abundant cation in the body and the second most abundant intracellular cation (3). It is an activator in ≈300 enzyme systems that are critical to cellular metabolism (4). Magnesium is essential in reactions involving ATP, which is required for glucose utilization, muscle contraction, and the synthesis of fat, protein, nucleic acid, and coenzymes (4). Other functions of magnesium include neurochemical transmission, skeletal muscle contraction, cardiac homeostasis, and the maintenance of normal intracellular concentrations of other cations (3).
Magnesium depletion is associated with biochemical and clinical derangements (3–5), which include impaired anabolic processes manifested by low serum albumin and serum protein concentrations and a decreased growth rate (5). Magnesium deficiency may contribute to cardiac arrhythmias, skeletal and respiratory muscle weakness, and seizures (3). Several mediators associated with the pathogenesis of cachexia are increased in magnesium deficiency (1). These include the inflammatory cytokines IL-1, IL-6, and TNF-α (2); PGE2 (6); and oxygen free radicals (2). In magnesium deficiency, not only are free radical concentrations higher than normal, but tissue concentrations of the antioxidants vitamin E, ascorbate, and glutathione are lower than normal; thus, endogenous antioxidant capacity is reduced, predisposing magnesium-deficient tissues to subsequent oxidative stress (2). The cytokine substance P, which increases early in magnesium deficiency, may lead to oxidative injury and appetite suppression, possibly contributing to the reduced food intake and weight loss that characteristically occur in experimental animals within 2 wk of dietary magnesium restriction (2).
Two surveys showed suboptimal magnesium intake among free-living adults in the United States. One survey, sponsored by the US Department of Agriculture (7), showed magnesium intakes that were 61.7% of the recommended dietary allowance (RDA; 8) among elderly people from food-insufficient households. A second study was conducted among well-educated, middle-to-upper class, community-dwelling volunteers in the Baltimore Longitudinal Study of Aging (9). In both men and women, median daily dietary intakes of magnesium failed to meet the 1989 RDA. Forty percent of the men and ≈50% of the women consumed less than two-thirds of the RDA for magnesium. The consequences of these marginal intakes of magnesium on health status are unknown and require further study.
Other studies provided data concerning the incidence of hypomagnesemia and of its associated mortality among hospitalized patients. In their study of an inner-city, medically disadvantaged, indigent population, Rubeiz et al (3) detected hypomagnesemia at the time of admission in 18% of ward and in 20% of intensive-care-unit patients. The mortality rates of the 2 groups of patients were approximately twice (P < 0.01) the rates of the normomagnesemic groups. They cited one study that reported low serum magnesium concentrations in up to 65% of intensive-care-unit patients, and another study that showed a higher mortality rate in hypomagnesemic postoperative patients than in their normomagnesemic counterparts.
Cognitive disorders, psychiatric disorders, and mental depression are occasional features of cachexia (1) and may be associated with hypomagnesemia (10). Levine et al (10) showed that patients with acute depressive disorders had elevations in the ratio of calcium to magnesium in both serum and cerebrospinal fluid. Hypomagnesemic patients have reported confusion, disorientation, agitation, hallucinations, and depression. Magnesium has been effective in alleviating depressive and manic symptoms in rapidly cycling bipolar disorders (10).
Possibly, magnesium deficiency contributes to diminished host defenses in the elderly (1). Elin (5) showed profound immunosuppressive capability in magnesium-deficient mice that had low numbers of antibody-synthesizing cells and low serum immunoglobulin concentrations. He cited studies in magnesium-depleted rats with decreased serum γ globulin and immunoglobulin G concentrations.
I suggest that magnesium deficiency in elderly patients contributes to cachexia. Magnesium deficiency puts the patient at risk of increased activity of damaging mediators that contribute to cachexia (eg, inflammatory cytokines, PGE2, and oxygen free radicals) and it reduces the tissues’ antioxidant capacity. Magnesium deficiency may increase the risk for cognitive and psychiatric disorders, which may be amenable to magnesium therapy (10).
It may be prudent to evaluate the magnesium status of elderly patients with cachexia. If these subjects are magnesium deficient, magnesium supplementation may be beneficial because magnesium supplementation is the best way to proceed to make sure that the correct amount of magnesium is ingested by the elderly.